Chronic Myeloid Leukemia: Therapy: Epidemiology, Prognosis, and Real Life Care
Elisabetta Abruzzese, et al.
The Abstract concludes: TKI therapy has allowed CML patients to pursue a normal life including planning/managing a family. Males do not need to stop therapy to conceive due to the therapy’s non-genotoxic nature, in contrast to females who must cease therapy due to the teratogenic nature of TKIs. Kinetics of regrowth of the CML residual disease during pregnancy in female patients is different than in TFR patients. To our knowledge this is the largest multicentric study regarding CML and reproduction. Results and practical management will be presented.
Fausto Castagnetti, et al.
The Abstract concludes: The risk distribution according to ELTS and Sokal score and the concordance between the two scores was different in young adults (< 30 years), adults (30-64 years) and elderly (≥ 65 years) patients, and the number of patients potentially misclassified by the Sokal score was particularly relevant in the elderly group. In elderly CML patients treated with IM or NIL as frontline therapy the ELTS score was able to predict the achievement of MR3 and MR4 and long-term leukemia-related survival, whereas the Sokal score was not able to find any significant difference. Consequently, especially in elderly patients, the use of ELTS score is strongly recommended to assess the baseline disease-risk and to select patients candidate to a frontline treatment with second generation TKIs, minimizing the risk of unnecessary over-treatment.
45 Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group
Giorgina Specchia, et al.
The Abstract concludes: Our preliminary results of this observational epidemiologic study suggest that collection of clinical data of CML patients treated out of strictly clinical trials represent an essential tool for long/term treatment, able to observe setting strategies based on the clinical characteristics, the degree of response obtained, and the toxicity related to the therapy in overall CML population. We are planning to continue to analyze all these endpoints to estimate the response and toxicity according to ELN guidelines, and feasibility of treatment sequence in a cohort of patients treated in real-life.
Katia B Pagnano, et al.
The Abstract concludes: The group treated with generic imatinib presented higher rate of failure at 3 months and lower OS, PFS and EFS at 24 months. Differences between the groups included a longer time to initiate treatment in the Generic group, a higher proportion of patients with b2a2 transcripts, which were related to an inferior rate of molecular responses and survival in other studies. There was no difference in the safety profile. The long-term impact in prognosis will be evaluated after a longer follow-up.
Juan Carlos Hernandez Boluda, et al.
The Abstract concludes: Our results confirm that treatment discontinuation is feasible and safe in clinical practice in Spain. Duration of TKI treatment of less than 5 years and a time in RM4.5 shorter than 4 years before TKI discontinuation were significantly associated with a higher incidence of molecular recurrence.
Marie Balsat, et al.
The Abstract concludes: The initiation of a TKI2 in newly diagnosed AP-CML pts induces excellent response and survival rates, probably superior to that of Imatinib first-line, and counterbalances the negative impact of this advanced disease, particularly in HEM AP subgroup.